arrow
I

Irene Braña

gustave roussy
H指数:47
被引数:1.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Integration of radiation therapy with systemic treatments in head and neck cancer: expert opinion and roadmap to consensus

头颈癌中放疗与全身治疗的整合:专家意见与共识路线图

2026-07-010
PRE
Genomic actionability and matched targeted therapy in a decade-long institutional precision medicine program for solid tumors

基因组可操作性及匹配的靶向疗法在为期十年的机构实体瘤精准医学项目中的应用

2025-11-060
OAAI
Head and Neck Cancer in Fanconi Anemia: Report of 11 Cases and a Systematic Review

范可尼贫血患者中的头颈部癌:11例病例报告与系统综述

CANCERS
IF4.4
2025-01-220
OA
Petosemtamab (MCLA-158) monotherapy in previously treated (2L+) recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC): Phase II trial

Petosemtamab (MCLA-158)单药治疗经治(2L+)复发/转移性(r/m)头颈鳞状细胞癌(HNSCC):II期临床试验

2024-12-010
PRE
Generation of chimeric antigen receptor T cells targeting p95HER2 in solid tumors

靶向p95HER2的嵌合抗原受体T细胞的生成

2024-11-182
OA
Impact of treatment beyond progression (TBP) in patients treated with immunotherapy (IO) in phase I trials (Ph1)

免疫治疗(IO)在I期临床试验(Ph1)中,治疗超越进展(TBP)的影响

2024-09-010
PRE
Cancer Core Europe: Leveraging Institutional Synergies to Advance Oncology Research and Care Globally
2024-07-010
PRE
Quality and safety of research biopsies (RB) in oncology clinical trials

肿瘤学临床试验中研究活检 (RB) 的质量和安全性

2023-10-010
OA
An investigator-initiated phase I study to assess the safety and tolerability of ex vivo next-generation neoantigen-selected tumor-infiltrating lymphocyte (TIL) therapy in advanced immune checkpoint blockade (ICB) resistant solid tumors (NEXTGENTIL-ACT)

研究者启动的I期研究,以评估体外下一代新抗原选择的肿瘤浸润淋巴细胞 (TIL) 疗法在晚期免疫检查点阻断 (ICB) 耐药实体瘤中的安全性和耐受性 (nextgentil-act)

2023-10-010
PRE
Survival outcomes in phase I trial combining VCN-01 and durvalumab (MEDI4736) in subjects with recurrent/ metastatic head and neck squamous cell carcinoma refractory to previous immunotherapy treatment
2023-10-010
PRE